bioRxivMicrobiology
A human monoclonal 1 antibody blocking SARS-CoV-2 infection
C. Wang, W. Li, D. Drabek, N. M. A. Okba, R. van Haperen, A. D. M. E. Osterhaus, F. J. M. van Kuppeveld, B. L. Haagmans, F. Grosveld, B.-J. Bosch
Abstract
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV). This cross-neutralizing antibody targets a communal epitope on these viruses and offers potential for prevention and treatment of COVID-19.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
Z. Lv, Y.-Q. Deng, … X. Wang·SciencePeer-reviewed·Sep 18, 2020
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
P. Brouwer, T. Caniels, … M. van Gils·bioRxiv·May 12, 2020
- Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
X. Tian, C. Li, … T. Ying·Emerging Microbes & InfectionsPeer-reviewed·Feb 17, 2020
- A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
- Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
S. J. Zost, P. Gilchuk, … J. E. Crowe·bioRxiv·May 22, 2020
- Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
Y. Guo, A. Kawaguchi, … K. Murano·bioRxiv·Oct 1, 2020